Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

PUBLISH ONLY Journal of Thoracic Oncology

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection Takeshi Hanagiri, MD, PhD, Kenji Sugio,

Frank Detterbeck, MD Journal of Thoracic Oncology

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Lung Cancer with Localized Ground-Glass Attenuation Represents Early-Stage Adenocarcinoma in Nonsmokers Nobuhiko Seki, MD, Shigeki Sawada, MD, Masao.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma Ichiro Yoshino, MD, PhD, Daigo Kawano, MD, Taro Oba, MD, Koji.

PUBLISH ONLY Journal of Thoracic Oncology

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

Primary Pulmonary Collision Cancer Consisting of Large Cell Carcinoma and Adenocarcinoma Shoji Nakata, MD, Yoshika Nagata, MD, Masakazu Sugaya, MD, Manabu.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Carcinoma of the esophagus: Prognostic significance of histologic type

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

International Thymic Malignancies Interest Group: A Way Forward

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases Marc Riquet, MD, PhD, Patrick Bagan,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD, PhD, Makiko Mizukami, MD, PhD, Yoshinobu Ichiki, MD, PhD, Masakazu Sugaya, MD, PhD, Manabu Yasuda, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Kosei Yasumoto, MD, PhD Journal of Thoracic Oncology Volume 3, Issue 10, Pages 1127-1132 (October 2008) DOI: 10.1097/JTO.0b013e318186fafb Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Overall survival curves of patients according to smoking history. A, Overall survival curves of all patients according to smoking history. The 5-year survival rates were 66.8%, 56.2%, and 55.1% in never-smokers, smokers with PYI >20, and smokes with PYI ≤20, respectively. The prognosis was significantly poorer in the smokers with PYI >20 than that of the never-smokers (p = 0.001). B, The 5-year survival rates in patients at stage I were 83.2%, 77.8%, and 69.9% in the never-smokers, smokers with PYI ≤20, and smokers with PYI >20, respectively. In patients at stage I, the prognosis was also significantly poorer in the smokers with PYI >20 than that of the never-smokers (p = 0.007). C, The overall survival in the patients at stage II. There was no significant difference among the three groups (never-smoker; 45.0%, smokers with PYI ≤20; 42.9%, smokers with PYI >20; 53.9%). D, The overall survival in the patients at stage III. The 5-year survival rates were 42.0% in the never-smokers, 17.8% in smokers with PYI ≤20, and 35.5% in smokers with PYI >20. Journal of Thoracic Oncology 2008 3, 1127-1132DOI: (10.1097/JTO.0b013e318186fafb) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Overall survival curves of patients with adenocarcinoma according to smoking history. In the patients with adenocarcinoma, the 5-year survival rates were 70.3%, 59.1%, and 59.7% in never-smokers, smokers with PYI >20, and smokers with PYI ≤20, respectively. The never-smoker had a significantly more favorable prognosis than smokers with PYI >20 (p < 0.01). Journal of Thoracic Oncology 2008 3, 1127-1132DOI: (10.1097/JTO.0b013e318186fafb) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Cancer-specific survival curves of the patients according to smoking history. With the exception of death caused by unrelated disease, the 5-year survival rates were 70.2%, 67.3%, and 69.6% in never-smokers, smokers with PYI >20, and smokers with PYI ≤20, respectively. There was no significant difference. Journal of Thoracic Oncology 2008 3, 1127-1132DOI: (10.1097/JTO.0b013e318186fafb) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions